Lv1
30 积分 2024-06-24 加入
KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary
1个月前
已完结
c‐Cbl induced podocin ubiquitination contributes to the podocytes injury in diabetic nephropathy
4个月前
已完结
GSK3β: A ray of hope for the treatment of diabetic kidney disease
4个月前
已完结
c‐Cbl induced podocin ubiquitination contributes to the podocytes injury in diabetic nephropathy
4个月前
已完结
Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy
5个月前
已完结
A tale of two antibodies: obinutuzumab versus rituximab
8个月前
已完结
After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy
9个月前
已完结
Successful Treatment of Patients With Refractory PLA2R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases
10个月前
已完结
Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: Results from an international comparative study
10个月前
已完结
Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach
10个月前
已完结
皖公网安备34019202002308
